Greenblatt D J, Sellers E M, Koch-Weser J
J Clin Pharmacol. 1982 May-Jun;22(5-6):259-63. doi: 10.1002/j.1552-4604.1982.tb02671.x.
The extent of drug binding to plasma protein does not influence the concentration of unbound drug in plasma at steady state but does influence the interpretation of total drug concentrations. An increase in free fraction (reduction in the extent of binding) decreases the therapeutic and toxic ranges for total drug concentrations. Conversely, a reduction in free fraction (increase in the extent of binding) increases these ranges. Laboratories generally measure total rather than unbound drug concentrations, and clinicians must use caution in interpreting these total drug concentrations in clinical situations where the extent of binding of extensively bound drugs may be altered. Free drug serum or plasma concentrations are inherently more reliable indices of the intensity of drug action than are total concentrations. Methodology for routine measurement of free concentration is becoming available and should ultimately be utilized for therapeutic monitoring of drugs that are highly bound to protein.
药物与血浆蛋白结合的程度在稳态时不影响血浆中游离药物的浓度,但会影响对总药物浓度的解读。游离分数增加(结合程度降低)会减小总药物浓度的治疗范围和毒性范围。相反,游离分数降低(结合程度增加)会扩大这些范围。实验室通常测定的是总药物浓度而非游离药物浓度,在广泛结合型药物的结合程度可能发生改变的临床情况下,临床医生在解读这些总药物浓度时必须谨慎。与总浓度相比,游离药物血清或血浆浓度本质上是更可靠的药物作用强度指标。常规测定游离浓度的方法已逐渐可用,最终应将其用于对高度蛋白结合药物的治疗监测。